glyco-optimized rituximab

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameglyco-optimized rituximab
Drug Alias Nameanti-CD20 antibody (Biolex)anti-CD20 antibody (EPIcyte)anti-CD20 antibody (Synthon)BLX-301BLX-300
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunosuppressantsB-lymphocyte antigen CD20 inhibitors
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsArthritis, RheumatoidLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEPIcyte Pharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEPIcyte Pharmaceutical IncSynthon BvBiolex Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsArthritis, RheumatoidLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A